Ulthera® System for Treating Axillary Hyperhidrosis

Status Completed

Clinical Trial Summary

Up to 20 enrolled subjects will be treated. Subjects will receive two Ulthera® treatments on the axillas provided 30 days apart. Follow-up visits will occur at 7, 30, 90 and 180 days following the last treatment.

Protocol amendment: The study was expanded to enroll an additional 20 subjects into Group A.

Clinical Trial Description

This study is a prospective, single-center, randomized clinical trial. Up to 20 subjects who are naïve to Ultherapy for treatment of hyperhidrosis will be enrolled and treated at a 2.0mm depth at two different treatment densities (Group A and Group B).

Group A will include up to 10 treated subjects. Subjects receiving treatment in a 3 x 4 grid, 12 treatment squares, 60 lines of treatment per square, at one treatment depth (2.0mm), at 0.30 J of energy.

Group B will include up to 10 treated subjects. Subjects receiving treatment in a 3 x 4 grid, 12 treatment squares, 40 lines of treatment per square, at one treatment depth (2.0mm), at 0.30 J of energy.

Gravimetric sweat production measures and starch iodine tests will be completed at baseline, treatment visit #2, and at all follow-ups for all study groups. Digital images of the starch iodine test will be obtained. Hyperhidrosis Disease Severity Scale (HDSS) scores will be obtained at baseline, each treatment visit, and at all follow-ups for all study groups. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02286765
Study type	Interventional
Source	Merz North America, Inc.
Contact
Status	Completed
Phase	N/A
Start date	October 2014
Completion date	September 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03627468` - A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis	Phase 3
Completed	`NCT03658616` - Assessment of Efficacy and Safety of Topical Administration of 1% Glycopyrronium Bromide (GPB) in Patients With Primary Axillary Hyperhidrosis and the Assessment of Long-term Efficacy and Safety of Topical Administration of 1% GPB Cream in Patients With Primary Axillary Hyperhidrosis.	Phase 3
Completed	`NCT04599907` - Evaluation of N-SWEAT Patch for Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating	N/A
Completed	`NCT03037788` - Investigation of Ascending Concentrations of Glycopyrronium Bromide (GPB) in a Topical Formulation in Subjects With Axillary Hyperhidrosis	Phase 1
Terminated	`NCT01722461` - A Study of the Ulthera® System for the Treatment of Axillary Hyperhidrosis	N/A
Completed	`NCT05863104` - Assessment of Safety, Tolerability, Systemic Exposure and Efficacy of GPB Cream in Adolescents With Severe Primary Hyperhidrosis	Phase 2
Completed	`NCT02823340` - Fractionated Microneedle Radiofrequency for Treatment of Primary Axillary Hyperhidrosis	N/A
Not yet recruiting	`NCT04159610` - Assessment of Safety, Tolerability and Efficacy of 1% GPB Cream Versus Qbrexza® (Glycopyrronium) Cloth 2.4% Under Maximum-Use Conditions in Subjects With Primary Axillary Hyperhidrosis	Phase 2
Completed	`NCT01799824` - Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis	Phase 2
Completed	`NCT03785587` - A Safety Study of BBI-4000 Gel in Pediatric Patients With Axillary Hyperhidrosis	Phase 2
Completed	`NCT03054480` - Fractional Micro-Needle Radiofrequency and I Botulinum Toxin A for Primary Axillary Hyperhidrosis	N/A